Capricor Therapeutics met with the FDA last week for a type A meeting, during which CEO Linda Marbán aimed to explain to the ...

The regulatory body determined that PTC Therapeutics’ New Drug Application for vatiquinone did not provide sufficient ...

JPMorgan added PTC Therapeutics (PTCT) to the firm’s Analyst Focus List while keeping an Overweight rating on the shares with a $68 price target ...

BofA lowered the firm’s price target on PTC Therapeutics (PTCT) to $76 from $82 and keeps a Buy rating on the shares after the FDA issued a ...

The U.S. Food and Drug Administration has denied approval for PTC Therapeutics' oral medication for a rare genetic disorder ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a ...

The U.S. Food and Drug Administration has turned away PTC Therapeutics' proposed vatiquinone treatment for the rare, inherited neurodegenerative disorder Friedreich's ataxia over concerns about the ...

The Louisiana Legislative Auditor has completed a years-long investigation into the Josh Guillory administration, and ...

The state released limited voter data to the U.S. Department of Justice this week, but the DOJ says the moved does not comply ...

In this video interview, Meri Beckwith, Co-CEO of Lindus Health, discusses recent Complete Response Letters issued to Replimune and Capricor, explaining how shifts in FDA reviewers can affect ...

In this video interview, Meri Beckwith, Co-CEO of Lindus Health, examines how recent developments with Complete Response ...

The FDA reviews odronextamab's application for relapsed lymphoma, highlighting trial enrollment issues but confirming safety and efficacy.